celgene corp. Resources | BNET
On CNET: Touch-screen Mac rumors true?

BNET Industries

Celgene Corp. (CELG) is in the Pharma Industry

Revenue
Dec 31 2007
$1.4B
Profit
Dec 31 2007
$226.4M
Market Cap
Aug 27 2008
$32.2B

Latest News and Analysis

  • Incorporated: 1986
  • CEO: Dr. Sol J. Barer Ph.D.
  • Employees: 1,685

Celgene is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory diseases through regulation of cellular, genomic and proteomic targets. At Dec 31 2007, Co.'s key commercial stage products are REVLIMID® (lenalidomide), for treatment in combination with dexamethasone for multiple myeloma, and THALOMID® (thalidomide), for treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma and cutaneous manifestations of erythema nodosum leprosum. Co. also sells ALKERAN®, through a supply and distribution agreement with GlaxoSmithKline, and FOCALIN?, to Novartis Pharma AG.

Key Competitors

advertisement
Celgene Corp. Company Info

Board of Directors

Dr. Sol J. Barer Ph.D.

Chairman

Mr. Robert J. Hugin

Mr. Michael D. Casey

Mr. Rodman L. Drake

Dr. Arthur Hull Hayes Jr.

Dr. Gilla Kaplan Ph.D.

Mr. James J. Loughlin

Dr. Ernest Mario Ph.D.

Dr. Walter L. Robb Ph.D.

Contact Information

86 Morris Avenue

Summit, NJ

http://www.celgene.com

908 673-9000

NAICS Code

Pharmaceutical and Medicine Manufacturing: 32541
advertisement